Skip to content

Melanoma and MAPK Pathways

Most cited papers

  1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
  2. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations
  3. Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
  4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
  5. Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology · 2009 · 4,656 citations
  6. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine · 2011 · 4,600 citations
  7. Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery · 1992 · 4,357 citations

Metadata from OpenAlex (CC0).